Tohra Suneel, Duseja Ajay, Taneja Sunil, Kalra Naveen, Gorsi Ujjwal, Behera Arunanshu, Kaman Lileswar, Dahiya Divya, Sahu Srimanta, Sharma Balkrishan, Singh Virendra, Dhiman Radha K, Chawla Yogesh
Departments of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
J Clin Exp Hepatol. 2021 Nov-Dec;11(6):682-690. doi: 10.1016/j.jceh.2021.02.002. Epub 2021 Feb 11.
Hepatocellular carcinoma (HCC) has variable etiological risk factors. Radiofrequency ablation (RFA) and surgical resection (SR) are frequently used as curative treatment options. In the present study, we assessed the etiological factors and efficacy of RFA and SR in patients with unifocal HCC in a real-life setting.
Of 870 patients with HCC seen over a period of nine years, 785 patients were assessed for stage and etiological risk factors. Of these, 110 (14%) patients with single HCC who were either treated with RFA (n = 72) or SR (n = 38) were evaluated for their outcomes in terms of overall survival (OS) and disease-free survival (DFS) over 3 years.
Of 785 patients [median age 60 (range 51-65) years, males (n = 685, 87.3%)] with HCC, viral hepatitis [HBV and HCV with or without alcohol = 502 (63.9%)] was the most common etiology; nonalcoholic steatohepatitis (NASH) and alcohol as an etiology showed increase over the years. About 677 (86.2%) patients had evidence of cirrhosis; NASH and HBV were predominant causes in noncirrhotic patients. Even though the groups were not matched, in 110 patients subjected to either RFA [mean tumor size, 2.2 (1.9-2.8) cm] or SR [mean tumor size, 7.1 (4.8-9.7) cm], tumor progression was observed in 49 (68%) and 16 (42%) patients in RFA and SR groups, respectively, with superior DFS in the SR group ( < 0.01). Of total 31 deaths, 20 (27.8%) deaths were in the RFA group and 11 (28.9%) in the SR group with no difference in OS at 3 years.
Viral hepatitis with or without alcohol is the commonest etiological factor for HCC in Northern India; NASH and alcohol are increasing over the years. In a real-life setting, in patients with unifocal HCC, there is no difference in overall 3-year survival subjected to SR or RFA with better DFS in the SR group.
肝细胞癌(HCC)具有多种病因风险因素。射频消融(RFA)和手术切除(SR)是常用的根治性治疗选择。在本研究中,我们在实际临床环境中评估了单灶性HCC患者的病因因素以及RFA和SR的疗效。
在9年期间就诊的870例HCC患者中,对785例患者进行了分期和病因风险因素评估。其中,110例(14%)单发HCC患者接受了RFA(n = 72)或SR(n = 38)治疗,并评估了他们3年的总生存期(OS)和无病生存期(DFS)结局。
在785例HCC患者中[中位年龄60岁(范围51 - 65岁),男性(n = 685,87.3%)],病毒性肝炎[HBV和HCV伴或不伴酒精 = 502例(63.9%)]是最常见的病因;非酒精性脂肪性肝炎(NASH)和酒精作为病因的比例逐年增加。约677例(86.2%)患者有肝硬化证据;NASH和HBV是非肝硬化患者的主要病因。尽管两组未匹配,但在110例接受RFA[平均肿瘤大小,2.2(1.9 - 2.8)cm]或SR[平均肿瘤大小,7.1(4.8 - 9.7)cm]治疗的患者中,RFA组和SR组分别有49例(68%)和16例(42%)患者出现肿瘤进展,SR组的DFS更佳(<0.01)。在31例死亡患者中,RFA组有20例(27.8%)死亡,SR组有11例(28.9%)死亡,3年OS无差异。
在印度北部,伴或不伴酒精的病毒性肝炎是HCC最常见的病因因素;NASH和酒精的病因比例逐年增加。在实际临床环境中,对于单灶性HCC患者,SR或RFA治疗的3年总生存期无差异,但SR组的DFS更佳。